menu

Hepatic Encephalopathy Treatment Market

Schedule Call

Hepatic Encephalopathy Treatment Market

Hepatic Encephalopathy Treatment Market by Drug Class (Laxatives and Antibiotics), Route of Administration (Oral, Intravenous, and Rectal), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Outlook and Forecast 2023-2031

GR - 994570 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: April 26, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023 to 2031


Hepatic Encephalopathy Treatment Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 1.48 billion

Revenue Forecast in 2031

US$ 2.58 billion

CAGR

6.43%

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Drug Class, Route of Administration, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global hepatic encephalopathy treatment market was valued at US$ 1.48 billion in 2022 and is expected to register a revenue CAGR of 6.43% to reach US$ 2.58 billion by 2031.

Hepatic Encephalopathy Treatment Market Fundamentals

Hepatic encephalopathy (HE) is an often-temporary neurological condition caused by a liver malfunction. It often occurs in people with liver cirrhosis or other kinds of liver disease, and its severity can range from moderate to severe, with potentially fatal effects. The liver filters pollutants from the blood, including ammonia, a waste product of protein breakdown. The liver's capacity to detoxify ammonia is hindered by liver disease, resulting in its buildup in the blood. Elevated blood ammonia levels can subsequently breach the blood-brain barrier and impair brain function, resulting in hepatic encephalopathy.

There are numerous important developments and prospects in the field of hepatic encephalopathy (HE) that have the potential to influence its diagnosis, therapy, and results. Advances in diagnostic approaches, such as sophisticated imaging modalities such as magnetic resonance imaging (MRI) and spectroscopy, may enhance accuracy in identifying and measuring the severity of HE. These technologies can give precise information on brain function and changes in brain metabolites, which may assist in the early and accurate diagnosis of HE. Moreover, treatment regimens customized to individual patient requirements, including underlying liver disease, comorbidities, and unique presentations of hepatic encephalopathy, may result in improved results.

The hepatic encephalopathy (HE) treatment market is dynamic, with multiple market participants actively researching and marketing medicines to control this disease. Market players continually perform research and development efforts to create novel HE medicines. This encompasses the research and development of new medications aimed at different aspects of HE, such as ammonia metabolism, inflammation, gut microbiota, and neuroprotection. R&D activities are centered on increasing current therapies' safety, effectiveness, and tolerance while investigating novel therapeutic methods.

[47]

Hepatic Encephalopathy Treatment Market Dynamics 

The increased prevalence of hepatic encephalopathy is one of the major factors driving the demand for the global hepatic encephalopathy treatment market. The increased frequency of liver diseases such as cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) drives the HE therapies market. Hepatic encephalopathy is a prevalent consequence of liver illness, and as the prevalence of liver disease rises worldwide, so does the demand for effective HE therapies. According to the 2020 estimates by the Cleveland Clinic, up to 50% of people with liver cirrhosis develop signs of hepatic encephalopathy. Hepatic encephalopathy can lead to significant morbidity and mortality, making it a major public health concern. Therefore, there is an urgent need to develop novel and effective therapies to improve the outcomes of patients with this condition.

Advanced treatment alternatives, including novel pharmacological medications, medical technologies, and interventions, have broadened the therapeutic landscape for hepatic encephalopathy. These improvements have provided physicians with alternatives for controlling HE, increasing demand for effective and creative treatment regimens. Furthermore, by minimizing hospitalizations and improving patient outcomes, these therapeutic options can potentially enhance HE patients' quality of life while reducing healthcare systems' costs. Ongoing research and development are introducing many novel agents for managing hepatic encephalopathy. These drugs are at varying phases of development, with some requiring further research before they may be used routinely in clinical practice. Future research should concentrate on large-scale clinical trials with appropriate design, sample size, removal of biases, reporting of adverse events, and standardization of treatment results due to various shortcomings in the existing literature.

Governments and healthcare organizations are increasingly concentrating on improving healthcare access, encouraging early detection, and offering effective treatment choices for liver disorders such as hepatic encephalopathy. Furthermore, the increased frequency of liver diseases due to bad lifestyle practices, alcohol usage, and viral infections is fueling the growth of the hepatic encephalopathy treatment market. This has resulted in an upsurge in research and development activity for new medicines and pharmaceuticals to treat hepatic encephalopathy. 

Despite the increasing prevalence of hepatic encephalopathy and the availability of various treatment options, the high cost of treatment and lack of awareness among patients in developing countries remains significant restraining factor in the hepatic encephalopathy treatment market.

Hepatic Encephalopathy Treatment Market Ecosystem

the global hepatic encephalopathy treatment market is analyzed from the following perspectives: drug class, route of administration, and region.  

Hepatic Encephalopathy Treatment Market by Drug Class

[58]

Based on the drug class, the global hepatic encephalopathy treatment market is segmented into laxatives and antibiotics. 

The antibiotics segment dominated the global hepatic encephalopathy treatment market with a high revenue share in 2022. The high revenue share of the antibiotics segment can be attributed to the effectiveness of antibiotics in treating hepatic encephalopathy. Furthermore, antibiotics have been shown to improve outcomes in patients with hepatic encephalopathy by reducing the bacterial load in the gut and decreasing ammonia production. Probiotics have also been studied as a potential treatment for hepatic encephalopathy, as they can help restore the balance of gut bacteria and reduce inflammation.

Furthermore, the laxatives segment is expected to show significant growth during the forecast period due to its ability to reduce ammonia levels in the body and improve bowel movements. Additionally, they can improve bowel movements and reduce the risk of complications such as constipation and fecal impact. 

Hepatic Encephalopathy Treatment Market by Route of Administration

Based on the route of administration, the global hepatic encephalopathy treatment market is segmented into oral, intravenous, and rectal. 

In 2022, the oral segment accounted for most of the global hepatic encephalopathy treatment market share. This can be attributed to the ease of administration and patient preference for oral medications. Moreover, oral medications have higher bioavailability compared to other routes of administration, which means that more of the medication is absorbed into the bloodstream and can be more effective in treating the condition. 

Intravenous drugs for hepatic encephalopathy include lactulose, rifaximin, and sodium benzoate. These drugs help reduce the buildup of toxins in the blood and improve brain function in patients with liver disease.  

The rectal segment is expected to show high growth in the forecast period. This mode of administration allows for faster and more efficient absorption of the medication, leading to quicker relief of symptoms. 

Hepatic Encephalopathy Treatment Market by Distribution Channel

Based on the distribution channel, the global hepatic encephalopathy treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

Hospital pharmacies accounted for the majority of the market revenue share in 2022. This is majorly due to the increasing number of patients being admitted to hospitals and the growing demand for specialized medication and equipment in these facilities. Additionally, hospital pharmacies often have a larger budget and more resources than retail pharmacies, allowing them to offer a wider range of services and products. 

The retail pharmacies segment is expected to grow in the forecast years. This growth can be attributed to the increasing number of retail pharmacies and the ease of patient access to medication. Additionally, the retail pharmacies segment offers personalized consultation and guidance to patients, which further drives its growth. 

Hepatic Encephalopathy Treatment Market by Region

Based on the region, the global hepatic encephalopathy treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for most of the market revenue share for the hepatic encephalopathy treatment market in 2022. This is due to the region's high prevalence of liver diseases and the availability of advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness significant growth during the forecast period owing to increasing awareness about liver diseases and improving healthcare facilities. 

The presence of major players such as Mallinckrodt Pharmaceuticals, Valeant Pharmaceuticals International, Inc., and Abbott Laboratories characterizes the European hepatic encephalopathy treatment market. The market is expected to grow significantly due to the increasing prevalence of liver diseases and the rising demand for effective treatment options.

The Asia Pacific hepatic encephalopathy treatment market is expected to grow in the forecast years. This is due to the rising patient population of cirrhosis and other liver diseases. Moreover, increasing awareness about hepatic encephalopathy treatment options and the availability of advanced healthcare infrastructure in the region. The growing geriatric population and lifestyle changes are also expected to drive market growth.

Hepatic Encephalopathy Treatment Market Competitive Landscape

The hepatic encephalopathy treatment market is highly competitive due to several key players operating. These players focus on product development, strategic collaborations, and mergers & acquisitions to maintain their market position and expand their product portfolio. In addition, the increasing prevalence of liver diseases and the rising demand for effective hepatic encephalopathy treatments are expected to drive market growth in the coming years. However, stringent regulatory policies and the high cost of treatment may hinder market growth to some extent.

Some of the prominent companies having the largest revenue share in the global hepatic encephalopathy treatment market are, 

Frequently Asked Questions About This Report

The hepatic encephalopathy treatment market is expected to experience significant growth due to the increasing prevalence of chronic liver diseases. Additionally, technological advancements can contribute to the expansion of the hepatic encephalopathy treatment market.

According to the deep-dive market assessment study by Growth Plus Reports, the global hepatic encephalopathy treatment market was valued at US$ 1.48 billion in 2022.

Some of the major strategies adopted by key market players in the hepatic encephalopathy treatment market include mergers and acquisitions, collaborations, partnerships, and new product launches. These strategies help companies to expand their market presence and strengthen their position in the competitive landscape.

The antibiotics segment dominated the global hepatic encephalopathy treatment market with a high revenue share in 2022.

The global hepatic encephalopathy treatment market was valued at US$ 1.48 billion in 2022 and is expected to register a revenue CAGR of 6.43 % to reach US$ 2.58 billion by 2031.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    5. Epidemiology and Patient Population Forecast to 2031
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL HEPATIC ENCEPHALOPATHY TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Laxatives
    2. Antibiotics
  6. GLOBAL HEPATIC ENCEPHALOPATHY TREATMENT MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral 
    2. Intravenous 
    3. Rectal
  7. GLOBAL HEPATIC ENCEPHALOPATHY TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies             
    2. Retail Pharmacies     
    3. Online Pharmacies    
  8. GLOBAL HEPATIC ENCEPHALOPATHY TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Hepatic Encephalopathy Treatment Market
      1. North America Hepatic Encephalopathy Treatment Market, By Drug Class
      2. North America Hepatic Encephalopathy Treatment Market, By Route of Administration 
      3. North America Hepatic Encephalopathy Treatment Market, By Distribution Channel 
      4. North America Hepatic Encephalopathy Treatment Market, by Country
        1. U.S.
          1. U.S. Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. U.S. Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. U.S. Hepatic Encephalopathy Treatment Market, By Distribution Channel
        2. Canada
          1. Canada Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Canada Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Canada Hepatic Encephalopathy Treatment Market, By Distribution Channel
    2. Europe Hepatic Encephalopathy Treatment Market
      1. Europe Hepatic Encephalopathy Treatment Market, By Drug Class 
      2. Europe Hepatic Encephalopathy Treatment Market, By Route of Administration 
      3. Europe Hepatic Encephalopathy Treatment Market, By Distribution Channel 
      4. Europe Hepatic Encephalopathy Treatment Market, by Country/Region
        1. Germany
          1. Germany Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Germany Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Germany Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        2. U.K.
          1. U.K. Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. U.K. Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. U.K. Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        3. France
          1. France Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. France Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. France Hepatic Encephalopathy Treatment Market, By Distribution Channel
        4. Spain
          1. Spain Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Spain Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Spain Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        5. Italy
          1. Italy Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Italy Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Italy Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        6. Rest of Europe 
          1. Rest of Europe Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Rest of Europe Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Rest of Europe Hepatic Encephalopathy Treatment Market, By Distribution Channel 
    3. Asia Pacific Hepatic Encephalopathy Treatment Market
      1. Asia Pacific Hepatic Encephalopathy Treatment Market, By Drug Class 
      2. Asia Pacific Hepatic Encephalopathy Treatment Market, By Route of Administration 
      3. Asia Pacific Hepatic Encephalopathy Treatment Market, By Distribution Channel 
      4. Asia Pacific Hepatic Encephalopathy Treatment Market, by Country/Region
        1. China
          1. China Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. China Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. China Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        2. Japan
          1. Japan Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Japan Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Japan Hepatic Encephalopathy Treatment Market, By Distribution Channel
        3. India
          1. India Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. India Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. India Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        4. South Korea
          1. South Korea Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. South Korea Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. South Korea Hepatic Encephalopathy Treatment Market, By Distribution Channel
        5. Australia
          1. Australia Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Australia Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Australia Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Distribution Channel 
    4. Latin America Hepatic Encephalopathy Treatment Market
      1. Latin America Hepatic Encephalopathy Treatment Market, By Drug Class 
      2. Latin America Hepatic Encephalopathy Treatment Market, By Route of Administration 
      3. Latin America Hepatic Encephalopathy Treatment Market, By Distribution Channel 
      4. Latin America Hepatic Encephalopathy Treatment Market, by Country/ Region
        1. Brazil
          1. Brazil Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Brazil Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Brazil Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        2. Mexico
          1. Mexico Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Mexico Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Mexico Hepatic Encephalopathy Treatment Market, By Distribution Channel
        3. Argentina
          1. Argentina Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Argentina Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Argentina Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        4. Rest of Latin America
          1. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Distribution Channel
    5. Middle East & Africa Hepatic Encephalopathy Treatment Market
      1. Middle East & Africa Hepatic Encephalopathy Treatment Market, By Drug Class 
      2. Middle East & Africa Hepatic Encephalopathy Treatment Market, By Route of Administration 
      3. Middle East & Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel 
      4. Middle East & Africa a Hepatic Encephalopathy Treatment Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. GCC Countries Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. GCC Countries Hepatic Encephalopathy Treatment Market, By Distribution Channel 
        2. South Africa
          1. South Africa Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. South Africa Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. South Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Drug Class 
          2. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Route of Administration 
          3. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel 
  9. COMPANY PROFILES         
    1. ASKA Pharmaceutical 
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Cosmo Pharmaceuticals N.V.
    3. Lupin Limited
    4. Kaleido Biosciences
    5. Kannalife Sciences, Inc.
    6. Bausch Health Companies Inc.
    7. Mallinckrodt Pharmaceuticals
    8. Abbott Laboratories
    9. Norgine B.V.
    10. QR Science and Technology Development Co., Ltd.

*Insights on financial performance are subject to the availability of information in the public domain

 

List of Tables

  1. Global Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million)
  2. Global Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  3. Global Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  4. Global Hepatic Encephalopathy Treatment Market, by Region, 2021-2031 (US$ Million) 
  5. North America Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  6. North America Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  7. North America Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  8. North America Hepatic Encephalopathy Treatment Market, by Country, 2021-2031 (US$ Million) 
  9. U.S. Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million)
  10. U.S. Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  11. U.S. Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  12. Canada Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  13. Canada Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  14. Canada Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  15. Europe Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  16. Europe Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  17. Europe Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  18. Europe Hepatic Encephalopathy Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  19. Germany Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  20. Germany Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  21. Germany Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million)
  22. U.K. Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  23. U.K. Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  24. U.K. Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million
  25. France Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  26. France Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  27. France Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  28. Italy Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  29. Italy Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  30. Italy Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  31. Spain Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  32. Spain Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  33. Spain Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  34. Rest of Europe Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  35. Rest of Europe Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  36. Rest of Europe Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  37. Asia Pacific Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  38. Asia Pacific Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  39. Asia Pacific Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  40. Asia Pacific Hepatic Encephalopathy Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  41. China Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  42. China Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  43. China Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  44. Japan Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  45. Japan Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  46. Japan Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  47. India Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  48. India Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  49. India Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  50. South Korea Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  51. South Korea Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  52. South Korea Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  53. Australia Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  54. Australia Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  55. Australia Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  56. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  58. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million)
  59. Latin America Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  60. Latin America Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  61. Latin America Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  62. Latin America Hepatic Encephalopathy Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  63. Brazil Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  64. Brazil Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  65. Brazil Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  66. Mexico Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  67. Mexico Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  68. Mexico Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  69. Argentina Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  70. Argentina Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  71. Argentina Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  72. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  73. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  74. Rest of Latin America Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million)
  75. Middle East and Africa Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  76. Middle East and Africa Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  77. Middle East and Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel 2021–2031 (US$ Million)
  78. Middle East and Africa Hepatic Encephalopathy Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  79. GCC Countries Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  80. GCC Countries Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  81. GCC Countries Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  82. South Africa Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  83. South Africa Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  84. South Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million) 
  85. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Drug Class, 2021-2031 (US$ Million) 
  86. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Route of Administration, 2021-2031 (US$ Million)
  87. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, By Distribution Channel, 2021–2031 (US$ Million)

 

List of Figures

  1. Hepatic Encephalopathy Treatment Market Ecosystem  
  2. Snapshot of Global Hepatic Encephalopathy Treatment Market, 2021 & 2031 
  3. Snapshot of Global Hepatic Encephalopathy Treatment Market, by Region, 2021 & 2031 
  4. Global Hepatic Encephalopathy Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Hepatic Encephalopathy Treatment Market: Key Players & Competitive Positioning (2022) 
  6. Stem cell manufacturing: Market Dynamics 
  7. Global Hepatic Encephalopathy Treatment Market for Laxative, 2021-2031 (US$ Million) 
  8. Global Hepatic Encephalopathy Treatment Market for Antibiotics, 2021-2031 (US$ Million) 
  9. Global Hepatic Encephalopathy Treatment Market for Oral, 2021-2031 (US$ Million) 
  10. Global Hepatic Encephalopathy Treatment Market for Intravenous, 2021-2031 (US$ Million) 
  11. Global Hepatic Encephalopathy Treatment Market for Rectal, 2021-2031 (US$ Million)
  12. Global Hepatic Encephalopathy Treatment Market for Hospital Pharmacies, 2021-2031 (US$ Million) 
  13. Global Hepatic Encephalopathy Treatment Market for Retail Pharmacies, 2021-2031 (US$ Million) 
  14. Global Hepatic Encephalopathy Treatment Market for Online Pharmacies, 2021-2031 (US$ Million) 
  15. North America Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  16. U.S. Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  17. Canada Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  18. Europe Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  19. Germany Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  20. U.K. Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  21. France Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  22. Italy Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  23. Spain Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  24. Rest of Europe Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  25. Asia Pacific Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  26. China Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  27. Japan Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  28. India Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  29. South Korea Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  30. Australia Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  31. Rest of Asia Pacific Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  32. Latin America Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  33. Brazil Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  34. Mexico Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  35. Argentina Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million)
  36. Rest of Latin America Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million)
  37. Middle East & Africa Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  38. GCC Countries Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  39. South Africa Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million) 
  40. Rest of Middle East & Africa Hepatic Encephalopathy Treatment Market, 2021-2031 (US$ Million)
  41. ASKA Pharmaceutical Revenue from 2019 Onwards (US$ Million)
  42. Cosmo Pharmaceuticals N.V. Revenue from 2019 Onwards (US$ Million)
  43. Lupin Limited Revenue from 2019 Onwards (US$ Million)
  44. Kaleido Biosciences Revenue from 2019 Onwards (US$ Million)
  45. Kannalife Sciences, Inc. Revenue from 2019 Onwards (US$ Million)
  46. Bausch Health Companies Inc. Corporation Revenue from 2019 Onwards (US$ Million)
  47. Mallinckrodt Pharmaceuticals Revenue from 2019 Onwards (US$ Million)
  48. Abbott Laboratories Revenue from 2019 Onwards (US$ Million)
  49. Norgine B.V. Revenue from 2019 Onwards (US$ Million)
  50. QR Science and Technology Development Co., Ltd. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Hepatic Encephalopathy Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Hepatic Encephalopathy Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports